Request To Download Free Sample of This Strategic Report @ Highlighted with 70 tables and 52 figures, this 132-page report ?Europe Small Molecule API Market 2022-2032 by Source (Synthetic, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 119 tables and 84 figures, this 187-page report ?Global Small Molecule API Market 2022-2032 by Source (Synthetic, ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Bioanalytical Testing Services Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and co ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

STA Pharmaceutical Hong Kong Investment, the shareholder of WUXI XDC (02268.HK), placed 37.8 million shares of the company at $30.855-31.515 per share, a discount of 4.5-6.5% to last Friday's ...

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences ...